Aclaris Therapeutics (ACRS): Trial Delay Will Not Impact Launch Timeline, Raising PT - Jefferies

August 12, 2016 8:38 AM EDT
Get Alerts ACRS Hot Sheet
Price: $22.49 +1.67%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ACRS Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Aclaris Therapeutis (NASDAQ: ACRS) after the company reported a Q2 loss of $12.9M (in line with the Jefferies estimate of $12.5M). Both the SK & warts A-101 trials have completed enrollment but topline data for the Ph3 SK program is now expected in Q4 instead of vs Q3, due to an enrollment imbalance issue. This does not change the commercialization timeline which is still on track for 1H18, assuming approval.

The price target of $23 is up from $20 on the 22.5x FY20 EPS of $2.00, discounted at 25% for 2.5 years (vs 3).

For an analyst ratinAclaris Therapeutics (NASDAQ: ACRS)
gs summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $19.14 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment